Today's jam-packed edition includes breaking news on a most-favored-nation drug policy and reconciliation legislation; also tariffs and an FDA-approved CRISPR pig. (843 words, 4 minutes, 12 seconds)
The Biotechnology Innovation Organization (BIO) offers this submission in response to the request by the Department of Commerce for comments on section 232 national security investigation of imports of pharmaceuticals and pharmaceutical ingredients. This investigation presents a critical opportunity to examine the intricacies of biotechnology supply chains and chart a path forward that strengthens national resilience while keeping the United States at the forefront of scientific innovation.
Council for State Biotechnology Associations (CSBA) • Letters, Testimony & Comments • May 7, 2025
The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory-based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative life-sustaining and life-saving biotechnology solutions. Convened by the Biotechnology Innovation Organization (BIO), CSBA’s collective voice represents the true grassroots network of innovators, researchers, manufacturers, and accelerators across the country. According to a recent industry report, U.S. bioscience industry employment in 2023 reached 2.3 million jobs in more than 149,000 businesses across every state in the U.S. and Puerto Rico. The total economic impact of the bioscience industry on the U.S. economy, as measured by overall output, totaled $3.2 trillion dollars in 2023.
Today, we take a deep dive into what’s been happening in the state legislatures—here’s what BIO’s watching related to healthcare and agriculture. Plus, two bills designed to strengthen U.S. patents were introduced May 1. (790 words, 3 minutes, 57 seconds)
Human Health, Disease Area • Toolkit • May 2, 2025
The ORPHAN Cures Act reaffirms Congress’s strong, bipartisan commitment to protect the research and development of new treatments for patients with rare diseases. A rare disease is one that affects fewer than 200,000 people, and while that may seem small, the facts show rare diseases are far from rare.
Since 2003, BioSafe, BIO's preclinical safety committee, has been driving innovation in biopharmaceuticals by addressing key regulatory and scientific issues. With over 300 members, we focus on expediting time to market and collaborate closely with BIO’s Cell and Gene Therapy Non-Clinical Task Force.
BIO launches a new campaign to explain why we vaccinate – and why it's good for America. We have details, plus how drug companies are investing in U.S. manufacturing, news on drug prices and IP, and more. (740 words, 3 minutes, 42 seconds)
